Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: PTC Therapeutics, Inc.

Market Cap 6.72B 5.9B 5.44B 5.09B 9.53B 636B 9.7B 65.27B 25.27B 312B 25.21B 24.67B 1,085B P/E 2026 *
91.4x
P/E 2027 * 32.4x
Enterprise Value 4.93B 4.33B 3.99B 3.74B 7B 467B 7.12B 47.94B 18.56B 229B 18.51B 18.12B 797B EV / Sales 2026 *
4.2x
EV / Sales 2027 * 3.71x
Free-Float
92.62%
Yield 2026 *
-
Yield 2027 * -
1 day+1.45%
1 week+12.09%
Current month+11.21%
1 month+21.40%
3 months+23.65%
6 months+5.70%
Current year+8.12%
1 week 74.86
Extreme 74.865
83.05
1 month 67.16
Extreme 67.165
83.05
Current year 61.43
Extreme 61.43
83.05
1 year 43.18
Extreme 43.175
87.5
3 years 17.53
Extreme 17.53
87.5
5 years 17.53
Extreme 17.53
87.5
10 years 4.03
Extreme 4.03
87.5
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2023
Director of Finance/CFO 41 13/07/2023
Chief Tech/Sci/R&D Officer - 01/10/2017
Director TitleAgeSince
Chairman 74 01/11/2004
Chairman 80 31/03/1998
Director/Board Member 65 01/12/2005
Date Insider Type Main position Quantity % Market Cap.
06-10Sell

Executive/Senior Manager

-56,409 0.0680%
05-15Fiscal year

General Counsel

8,436 0.0102%
05-14Sell

Chief Executive Officer

-12,572 0.0152%
Change 5-day change 1-year change 3-year change Capi.($)
+1.45%+12.09%+65.58%+98.00% 6.72B
+0.45%-1.37%+43.66%+141.28% 983B
+3.37%+1.66%+58.00%+44.48% 557B
+2.07%+5.52%+27.75%+72.72% 406B
+1.53%-1.93%+23.33%+16.35% 314B
+2.26%+2.95%+30.77%+17.16% 273B
+2.61%+2.66%+30.07%+37.04% 272B
+2.60%+7.76%-35.32%-43.32% 203B
+0.66%-0.24%+27.37%+52.79% 186B
+0.14%-1.71%+17.76%+61.42% 155B
Average +1.77%-0.28%+28.90%+49.79% 335.71B
Weighted average by Cap. +1.69%-2.20%+33.22%+66.81%

Financials

2026 *2027 *
Net sales 1.17B 1.03B 950M 889M 1.67B 111B 1.69B 11.4B 4.41B 54.53B 4.4B 4.31B 190B 1.31B 1.15B 1.06B 995M 1.86B 124B 1.89B 12.76B 4.94B 61B 4.93B 4.82B 212B
Net income 65.46M 57.5M 52.99M 49.6M 92.93M 6.2B 94.5M 636M 246M 3.04B 246M 240M 10.57B 178M 156M 144M 135M 253M 16.85B 257M 1.73B 669M 8.27B 668M 653M 28.74B
Net Debt -1.78B -1.57B -1.44B -1.35B -2.53B -169B -2.58B -17.34B -6.71B -82.91B -6.7B -6.55B -288B -1.84B -1.62B -1.49B -1.39B -2.61B -174B -2.66B -17.89B -6.92B -85.53B -6.91B -6.76B -297B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
24/06/26 $82.13 +1.45% 2,307,232
22/06/26 $80.96 +2.51% 2,414,051
18/06/26 $78.98 +0.57% 2,870,286
17/06/26 $78.53 +7.18% 3,183,591
16/06/26 $73.27 -4.56% 6,044,172
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
80.96USD
Average target price
93.93USD
Spread / Average Target
+16.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!